Stockscreener 앱 받기
95.38
0.88%
-0.85
시간 외 거래:
96.00
0.62
+0.65%
전일 마감가:
$96.23
열려 있는:
$95.82
하루 거래량:
781.61K
Relative Volume:
1.09
시가총액:
$22.89B
수익:
$3.30B
순이익/손실:
$-501.07M
주가수익비율:
-45.11
EPS:
-2.1146
순현금흐름:
$1.03B
1주 성능:
-4.11%
1개월 성능:
-20.52%
6개월 성능:
-15.05%
1년 성능:
+3.69%
1일 변동 폭
$94.50
$96.05
1주일 범위
$94.50
$102.82
52주 변동 폭
$76.53
$131.49
바이오앤테크 Stock (BNTX) Company Profile
BNTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
95.38 | 22.89B | 3.30B | -501.07M | 1.03B | -2.1146 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.20 | 129.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
658.48 | 71.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
615.02 | 37.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.34 | 36.68B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
251.98 | 27.10B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오앤테크 Stock (BNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-01-10 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-02 | 재확인 | BMO Capital Markets | Outperform |
| 2024-11-19 | 개시 | Berenberg | Buy |
| 2024-11-19 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-11-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-09-24 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-08-02 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-14 | 개시 | Evercore ISI | In-line |
| 2024-02-23 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-05 | 개시 | Oppenheimer | Perform |
| 2023-12-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-10-16 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-17 | 업그레이드 | Redburn | Neutral → Buy |
| 2022-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-08-17 | 개시 | Cowen | Market Perform |
| 2022-07-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2021-12-16 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-11-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-08-11 | 업그레이드 | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-06-16 | 다운그레이드 | Redburn | Neutral → Sell |
| 2021-05-18 | 개시 | Goldman | Neutral |
| 2021-05-11 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-08-03 | 재개 | Berenberg | Buy |
| 2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-06-30 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-03-09 | 개시 | H.C. Wainwright | Neutral |
| 2020-01-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-11-05 | 개시 | Wolfe Research | Outperform |
| 2019-11-04 | 개시 | Berenberg | Buy |
| 2019-11-04 | 개시 | BofA/Merrill | Buy |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-11-04 | 개시 | JP Morgan | Overweight |
| 2019-11-04 | 개시 | SVB Leerink | Outperform |
| 2019-11-04 | 개시 | UBS | Buy |
모두보기
바이오앤테크 주식(BNTX)의 최신 뉴스
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
BioNTech’s Earnings Call: Oncology Growth Amidst Challenges - TipRanks
BioNTech’s 2024 Earnings Highlight Oncology Focus - TipRanks
BioNTech Earnings: 2025 Guidance Disappoints, Fair Value Lowered - Morningstar
BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat - Morningstar
Jefferies maintains BioNTech stock Buy rating, $149 target - Investing.com India
Earnings call transcript: BioNTech beats Q4 2024 expectations, stock dips - Investing.com
BioNTech Surpasses Q4 Revenue Estimates - The Motley Fool
US Stocks Likely To Open Lower After Trump Hints At Looming Recession: Expert Says Can't Rule Out A Bear Market As Indices Inch Towards Correction Territory - Benzinga
BioNTech reports Q4 EPS EUR 1.08 vs. EUR 1.88 last year - TipRanks
Here's Why Moderna Stock Soared 16% On Wednesday - Barchart
Here's Why Moderna Stock Soared 16% on Wednesday - Yahoo Finance
BioNTech SE's RNA-based vaccine for malaria placed on clinical hold by FDA - MSN
Paramount Group Inc (PGRE) Shares Soar Above 1-Year High - The News Heater
Pfizer and BioNTech violated COVID-19 vaccine patent held by Moderna, German court rules - The Globe and Mail
BioNTech stock falls after FDA clinical hold on malaria vaccine trial - Investing.com
BioNTech SEADR to Host Earnings Call - ACCESS Newswire
AASTOCKS Financial NewsBioNTech SE (BNTX) - AASTOCKS.com
Are Medical Stocks Lagging Auna S.A. (AUNA) This Year? - MSN
What Makes BioNTech (BNTX) a New Buy Stock - Yahoo Finance UK
BioNTech SE ADR (BNTX) did well last session? - US Post News
Electronic Arts Posts Upbeat Earnings, Joins Mattel, Johnson Controls, Mueller Water Products And Other Big Stocks Moving Higher On WednesdayBloom Energy (NYSE:BE), BigBear.ai Hldgs (NYSE:BBAI) - Benzinga
Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales - Barchart
Moderna and BioNTech shares fall after Senate committee vote on RFK Jr. - Investing.com
Hesai Group ADR (HSAI) shows promising results - US Post News
(PDF) Spontaneous reporting of adverse reactions associated with the COVID-19 vaccine in health care professionals: A descriptive observational study conducted in a Portuguese hospital - ResearchGate
Will Non-COVID Drugs Drive PFE's Top Line in Q4 Earnings? - Yahoo Finance
Validea Benjamin Graham Strategy Daily Upgrade Report1/31/2025 - Nasdaq
BioNTech's SWOT analysis: oncology pipeline, cash boost stock outlook - Investing.com
Stocks To Watch: BioNTech ADR Sees Relative Strength Rating Rise To 84 - Investor's Business Daily
Wall Street Analysts Predict a 25.59% Upside in BioNTech (BNTX): Here's What You Should Know - MSN
Years-Old List of Alleged Pfizer COVID-19 Vaccine 'Side Effects' Is Misleading - Snopes.com
BioNTech Expands Cancer Drug Pipeline: Launches Key Lung Cancer Trials, Advances Immunotherapy Programs - StockTitan
Why BioNTech (BNTX) Shares Are Volatile TodayBioNTech (NASDAQ:BNTX) - Benzinga
BioNTech SE ADR falls Wednesday, underperforms market - MarketWatch
Vaccine Stocks Jump After CDC Reports First US Bird-Flu Death - Yahoo Finance
BioNTech SE ADR rises Tuesday, outperforms market - MarketWatch
Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike - Investor's Business Daily
BioNTech SE ADR rises Monday, outperforms market - MarketWatch
BNTX: 3 Genomic Stocks Unlocking the Secrets of DNA - StockNews.com
BioNTech SE ADR rises Friday, still underperforms market - MarketWatch
바이오앤테크 (BNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.04%
0.60%
자본화:
|
볼륨(24시간):